Suppr超能文献

在赞比亚南部扩大快速床边检测以进行婴儿早期艾滋病毒诊断的成本效益。

The cost-effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern Zambia.

机构信息

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.

出版信息

PLoS One. 2021 Mar 9;16(3):e0248217. doi: 10.1371/journal.pone.0248217. eCollection 2021.

Abstract

INTRODUCTION

Early infant diagnosis (EID) and treatment can prevent much of the HIV-related morbidity and mortality experienced by children but is challenging to implement in sub-Saharan Africa. Point-of-care (PoC) testing would decentralize testing and increase access to rapid diagnosis. The objective of this study was to determine the cost-effectiveness of PoC testing in Southern Province, Zambia.

METHODS

A decision tree model was developed to compare health outcomes and costs between the standard of care (SoC) and PoC testing using GeneXpert and m-PIMA platforms. The primary health outcome was antiretroviral treatment (ART) initiation within 60 days of sample collection. Additional outcomes included ART initiation by 12 months of age and death prior to ART initiation. Costs included both capital and recurrent costs. Health outcomes and costs were combined to create incremental cost effectiveness ratios (ICERs).

RESULTS

The proportion of children initiating ART within 60 days increased from 27.8% with SoC to 79.8-82.8% with PoC testing depending on the algorithm and platform. The proportion of children initiating ART by 12 months of age increased from 50.9% with SoC to 84.0-86.5% with PoC testing. The proportion of HIV-infected children dying prior to ART initiation decreased from 18.1% with SoC to 3.8-4.6% with PoC testing. Total program costs were similar for the SoC and GeneXpert but higher for m-PIMA. ICERs for PoC testing were favorable, ranging from $23-1,609 for ART initiation within 60 days, $37-2,491 for ART initiation by 12 months of age, and $90-6,188 for deaths prior to ART initiation. Factors impacting the costs of PoC testing, including the lifespan of the testing instruments and integrated utilization of PoC platforms, had the biggest impact on the ICERs. Integrating utilization across programs decreased costs for the EID program, such that PoC testing was cost-saving in some situations.

CONCLUSION

PoC testing has the potential to improve linkage to care and ART initiation for HIV-infected infants and should be considered for implementation within EID programs to achieve equity in access to HIV services and reduce HIV-related pediatric morbidity and mortality.

摘要

简介

早期婴儿诊断(EID)和治疗可以预防撒哈拉以南非洲地区许多与 HIV 相关的发病率和死亡率,但在实施方面具有挑战性。即时检测(PoC)可将检测去中心化,增加快速诊断的可及性。本研究的目的是确定赞比亚南部省使用 GeneXpert 和 m-PIMA 平台进行即时检测的成本效益。

方法

使用决策树模型比较了标准护理(SoC)和使用 GeneXpert 和 m-PIMA 平台进行即时检测的成本效益。主要健康结果是在采集样本后 60 天内开始接受抗逆转录病毒治疗(ART)。其他结果包括 12 个月内开始接受 ART 和在开始接受 ART 之前死亡。成本包括资本和经常性成本。将健康结果和成本结合起来,计算出增量成本效益比(ICER)。

结果

根据算法和平台的不同,使用 PoC 检测后 60 天内开始接受 ART 的儿童比例从 SoC 的 27.8%增加到 79.8-82.8%。12 个月内开始接受 ART 的儿童比例从 SoC 的 50.9%增加到 PoC 检测的 84.0-86.5%。在开始接受 ART 之前死亡的 HIV 感染儿童比例从 SoC 的 18.1%下降到 PoC 检测的 3.8-4.6%。SoC 和 GeneXpert 的总项目成本相似,但 m-PIMA 的成本更高。PoC 检测的 ICER 是有利的,在 60 天内开始接受 ART 的范围内为 23-1609 美元,在 12 个月内开始接受 ART 的范围内为 37-2491 美元,在开始接受 ART 之前死亡的范围内为 90-6188 美元。影响 PoC 检测成本的因素,包括检测仪器的使用寿命和 PoC 平台的综合利用,对 ICER 影响最大。在 EID 项目中整合利用可以降低 EID 项目的成本,因此在某些情况下,PoC 检测具有成本效益。

结论

即时检测有可能改善 HIV 感染婴儿的护理衔接和开始接受抗逆转录病毒治疗的机会,应考虑在 EID 项目中实施,以实现获得 HIV 服务的公平性并减少与 HIV 相关的儿科发病率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4525/7943017/366fdcbf79a8/pone.0248217.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验